SCHEMBL6374170

SCHEMBL6374170

CS(=O)(=O)c1ccccc1-c1ccc(CNC(=O)C(Cc2ccccc2)NC(=O)Nc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.53
ITGB3 P05106 2/20 0.48
ITGAV P06756 2/20 0.48
ANPEP P15144 1/20 0.47
NAMPT P43490 2/20 0.47
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
F10 P00742 2/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
RORC P51449 1/20 0.45
KLKB1 P03952 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
FPR2 P25090 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6375733 1.00 F7 (0.53) F7ITGB3ITGAVANPEPNAMPT
SCHEMBL6374164 1.00 F7 (0.53) F7ITGB3ITGAVANPEPNAMPT
SCHEMBL6374070 0.90 F10 (0.55) F10CA12CA1CA2CA9
SCHEMBL6380705 0.90 F10 (0.55) F10CA12CA1CA2CA9
SCHEMBL6374074 0.90 F10 (0.55) F10CA12CA1CA2CA9
SCHEMBL6376146 0.89 RORC (0.47) F7ITGB3ITGAVNAMPTRORC
SCHEMBL6374356 0.85 F2 (0.53) NAMPTF10MMP9CA12CA1
SCHEMBL6373360 0.85 F2 (0.53) NAMPTF10MMP9CA12CA1
SCHEMBL6373376 0.85 F2 (0.53) NAMPTF10MMP9CA12CA1
SCHEMBL6376317 0.84 FPR2 (0.59) F10CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050137230-A1 Carboxamide derivatives DORSCH DIETER (DE) 2005-06-23 US claimed
US-20040038858-A1 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours MERCK PATENT GMBH (DE) 2004-02-26 US claimed
US-20050137230-A1 Carboxamide derivatives DORSCH DIETER (DE) 2005-06-23 US disclosed
US-20040038858-A1 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours MERCK PATENT GMBH (DE) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137230-A1 Carboxamide derivatives F11, F12, F2 F7 60/4885ITGB3 1984/4885ITGAV 1605/4885
US-20040038858-A1 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours CNR2, CNR1, HCAR2 F7 509/4885ITGB3 3319/4885ITGAV 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.